Bright Minds Biosciences (US:DRUG) Globenewswire·2025-11-25 21:30Core Viewpoint - Bright Minds Biosciences, Inc. is focused on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other CNS disorders, and is participating in key upcoming healthcare events [1][2]. Company Overview - Bright Minds Biosciences is a biotechnology company dedicated to creating innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting critical brain receptors [2]. - The company aims to address conditions with high unmet medical needs, including epilepsy and depression, by delivering breakthrough therapies that can significantly improve patients' lives [2]. Product Development - Bright Minds has developed a unique platform of highly selective serotonergic agonists that exhibit selectivity at various serotonergic receptors, resulting in a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry [3]. Upcoming Events - The company will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 11:30 am ET [1]. - Additionally, Bright Minds will be present at the 2025 American Epilepsy Society Annual Meeting during the Scientific Exhibit Session on December 7, 2025, from 2 pm to 5 pm ET [1].